Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

In vitro technologies like 3D organoids and high-content imaging are advancing immuno-oncology by enabling detailed ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein ...

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Loss-of-function variants in genes encoding tumor suppressor proteins, such as those that mediate DNA repair and cell-cycle checkpoints, can also contribute to an unstable genome. A gene that ...

Patients were heavily pretreated and were refractory to brentuximab vedotin and anti-PD1 immune checkpoint ... cell infusion at three dose levels and three weekly infusions. At day 28 of each ...

Patients were heavily pretreated and were refractory to brentuximab vedotin and anti-PD1 immune checkpoint inhibitors ... followed by AFM13-NK cell infusion at three dose levels and three weekly ...